• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

What is the Association Between Postmenopausal Bleeding and Risk for Endometrial Cancer?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Postmenopausal bleeding (PMB) is a common symptom of endometrial cancer but also associated with benign conditions
    • Endometrial cancer varies from 3% to 25%
    • Data on PPV and sensitivity of PMB for endometrial cancer are limited
    • PPV depends on underlying prevalence
      • PPV will improve in high prevalence populations
    • Clarke et al. (JAMA Internal Medicine, 2018) assessed the risk of endometrial cancer in the setting of PMB

METHODS:

  • Systematic review and meta-analysis
  • Studies reporting on endometrial cancer and PMB correlation and risk assessment
  • Two independent authors selected and assessed studies for bias using accepted tools
  • Primary outcomes
    • Pooled prevalence of PMB in women with endometrial cancer
    • Risk of endometrial cancer in women with PMB

RESULTS:

  • 129 studies
    • 34,432 patients with PMB | 6,358 with endometrial cancer
  • Pooled prevalence of PMB among women with endometrial cancer was 91% (95% CI, 87%-93%), with no significant difference by stage
    • Stage 1: 94%
    • Stage II to IV: 84%
  • Risk of endometrial cancer among women with PMB was 9% (95% CI, 8%-11%), varying by
    • Hormone therapy (HT) excluded (12%) vs studies where HT was included (7%)
    • Geographic region: 5% (North America) to 13% (Western Europe)
    • Risk higher when enrollment was prior to 1990 (13%) vs 2010-2017 (8%)
  • Patients with a minimum endometrial thickness of 4-5 mm: 19%
  • Patients with polyps: 3%
  • Endometrial cancer was not associated with
    • Mean age | Years since menopause | Percentage of women using HT

CONCLUSION:

  • Detection strategies focused on PMB have potential to capture 90% of endometrial cancers
    • However, most women with PMB will not be diagnosed with endometrial cancer
  • Women with PMB and a minimum endometrial thickness (4-5mm), the pooled risk of endometrial cancer was 19%, approximately 2x the risk of the general pool
    • Polyp risk was lower than general pool
  • The authors state

As new markers are discovered or new clinical management strategies are evaluated, our results can aid in the assessment of their potential clinical value and will help to inform clinical and epidemiologic risk prediction models to support clinical decision making.

Learn More – Primary Sources:

Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Transvaginal Ultrasound in the Evaluation of Postmenopausal Bleeding
Endometrial Cancer: The Basics
Ovarian or Endometrial Cancer? Consider Lynch Syndrome

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site